IP Library Granted Patent US 12,053,227
Granted Patent B2
US 12,053,227 · App. 17/646,098 · Granted Aug 6, 2024

Methods of treating nasal airways

Inventors: Scott J. Wolf (Menlo Park, CA); Andrew Frazier (Sunnyvale, CA)
Assignee: Aerin Medical Inc.
A61B18/14A61B18/02A61B18/1206A61B18/1485A61N1/403A61B5/01A61B2017/248A61B17/2816A61B17/320068A61B2017/320069A61B2017/32007A61B2018/00005A61B2018/00023A61B2018/0016A61B2018/00178A61B2018/0022A61B2018/00327A61B2018/00577A61B2018/00595A61B2018/00642A61B2018/00702A61B2018/00708A61B2018/00791A61B2018/00821A61B2018/00875A61B2018/00886A61B2018/0091A61B2018/00922A61B2018/00982A61B2018/00994A61B2018/0212A61B2018/0225A61B2018/0262A61B18/06A61B18/085A61B18/12A61B2018/1253A61B2018/126A61B2018/1425A61B2018/143A61B18/1442A61B18/1445A61B18/1477A61B18/16A61B18/18A61B2018/1807A61B18/1815A61B2018/1861A61B18/20A61F5/08A61F5/56A61F7/10A61N5/025A61N5/0603A61N5/0625A61N7/022F04C2270/041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,053,227
App. No.
17/646,098
Granted
Aug 6, 2024
Kind
B2
Abstract

A device is described for treating a nasal airway by modifying a property of a nasal tissue of or near a nasal valve of the airway, without using a surgical incision or an implant, to decrease airflow resistance or perceived airflow resistance in the nasal airway. Various embodiments include an elongate shaft, a bipolar radiofrequency delivery member extending from one end of the shaft, and a handle attached to the elongate shaft at an opposite end from the radiofrequency delivery member. The radiofrequency delivery member is sized to be inserted into a nose and configured to at least temporarily deform the nasal tissue and deliver radiofrequency energy. The radiofrequency delivery member includes two rows of protruding electrodes disposed on a tissue contact surface, and the device is configured to deliver radiofrequency energy from one row of electrodes to the other row of electrodes.

Claims (29)

1. A device for reducing mucus secretion in an upper airway of a patient, the device comprising:

a malleable shaft having a proximal end and a distal end;

a handle at the proximal end of the malleable shaft;

a treatment tip at the distal end of the malleable shaft, the treatment tip comprising a treatment surface facing laterally, relative to the handle and the malleable shaft;

a first row of radiofrequency electrodes disposed along the treatment surface;

a second row of radiofrequency electrodes disposed along the treatment surface; and

a temperature sensor located between the first row of radiofrequency electrodes and the second row of radiofrequency electrodes.

2. The device of claim 1 , wherein the first and second rows of radiofrequency electrodes protrude from the treatment surface.

3. The device of claim 1 , wherein the first and second rows of radiofrequency electrodes are blunt-tipped electrodes.

4. The device of claim 1 , wherein the temperature sensor comprises a thermocouple.

5. The device of claim 1 , wherein the treatment surface is convex, with a radius of curvature that is perpendicular to a longitudinal axis of the malleable shaft and the handle.

6. A method for reducing mucus secretion in an upper airway of a patient, the method comprising:

bending a malleable shaft of a treatment device into a desired configuration;

advancing a treatment tip of the treatment device into a nostril of the patient to contact a laterally facing treatment surface of the treatment tip with mucosal tissue of the upper airway, without piercing the mucosal tissue;

delivering radiofrequency energy from a first electrode on the laterally facing treatment surface to a second electrode on the laterally facing treatment surface, to treat a target tissue underlying the mucosal tissue to modify a property of the target tissue and thus reduce mucus secretion;

measuring a temperature of the mucosal tissue, using a temperature sensor disposed on the laterally facing treatment surface between the first electrode and the second electrode; and

removing the treatment tip from the upper airway without leaving an implant in the upper airway.

7. The method of claim 6 , further comprising performing a test to determine whether a desired contact between the first electrode and the second electrode and the mucosal tissue has been achieved.

8. The method of claim 6 , further comprising adjusting an amount of radiofrequency energy delivery from the first electrode to the second electrode, based at least in part on the temperature measured with the temperature sensor.

9. The method of claim 6 , wherein the temperature sensor comprises a thermocouple.

10. The method of claim 6 , wherein the first electrode comprises a first row of electrodes, and wherein the second electrode comprises a second row of electrodes.

11. The method of claim 6 , wherein the mucosal tissue comprises tissue located on a nasal turbinate of the upper airway.

12. The method of claim 6 , wherein the mucosal tissue comprises tissue located on a posterior aspect of an inferior turbinate.

13. The method of claim 6 , wherein delivering the radiofrequency energy comprises delivering the radiofrequency energy in an amount that deactivates mucus producing cells by impairing at least one of mucus production ability or cell differentiation ability of the mucus producing cells.

14. The method of claim 6 , wherein delivering the radiofrequency energy comprises delivering the radiofrequency energy in an amount that causes one or more mucus paths of the upper airway to divert.

15. The method of claim 6 , further comprising:

bending the malleable shaft a second time;

advancing the treatment tip of the treatment device into the nostril again; and

delivering radiofrequency energy from the first electrode to the second electrode to treat a different target tissue underlying the mucosal tissue.

Assignments (2)
SECURITY INTEREST Recorded Dec 20, 2024
From: AERIN MEDICAL INC.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 069746/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2021
From: WOLFE, SCOTT J.; FRAZIER, ANDREW
To: AERIN MEDICAL INC.
Reel/Frame 058487/0793 →
Continuity (11)
Continuation 16514316 · Jul 17, 2019
Continuation 15596455 · May 16, 2017
Continuation 15248935 · Aug 26, 2016
Continuation 14864428 · Sep 24, 2015
Continuation 14737196 · Jun 11, 2015
Continuation 14607639 · Jan 28, 2015
Continuation 14026922 · Sep 13, 2013
Continuation In Part 13495844 · Jun 13, 2012
Provisional Application 61603864 · Feb 27, 2012
Provisional Application 61496930 · Jun 14, 2011
Related Publication 20220183741A1 · Jun 16, 2022
Cited By (12)
US 12,336,750 US 12,357,378 US 12,357,817 US 12,364,532 US 12,369,963 US 12,369,966 US 12,369,973 US 12,471,978 US 12,527,618 US 12,636,058 US 12,636,073 US 12,678,212